	US 12,134,782 B2
	T cells derived from umbilical cord blood
Mary Laughlin, Cleveland, OH (US); and Jeong Su Do, Cleveland, OH (US)
Assigned to Abraham J and Phyllis Katz Cord Blood Foundation, Cleveland, OH (US)
Appl. No. 16/479,253
Filed by Abraham J and Phyllis Katz Cord Blood Foundation, Cleveland, OH (US)
PCT Filed Jan. 29, 2018, PCT No. PCT/US2018/015667 § 371(c)(1), (2) Date Jul. 19, 2019, PCT Pub. No. WO2018/140850, PCT Pub. Date Aug. 2, 2018.
Claims priority of provisional application 62/595,243, filed on Dec. 6, 2017.
Claims priority of provisional application 62/552,119, filed on Aug. 30, 2017.
Claims priority of provisional application 62/451,364, filed on Jan. 27, 2017.
Prior Publication US 2019/0376032 A1, Dec. 12, 2019
Int. Cl. C12N 5/0783 (2010.01); A61K 35/17 (2015.01)

CPC C12N 5/0637 (2013.01) [A61K 35/17 (2013.01); C12N 2501/15 (2013.01); C12N 2501/2302 (2013.01); C12N 2502/1358 (2013.01)]

17 Claims

1. An inducible regulatory T cell composition comprising an expanded iTreg composition produced by a method comprising:

providing human umbilical cord blood;

isolating naïve CD4⁺T cells from the human umbilical cord blood;

inducing the naïve CD4⁺T cells to differentiate into a first composition comprising iTregs by treating the naïve CD4⁺T cells with TGF-β;

separating the iTregs from the first composition to form a substantially purified iTreg composition; and

expanding the purified iTreg composition in a composition comprising a mesenchymal stromal cell (MSC) feeder layer and IL-2 to form an expanded human iTreg composition expressing CD4⁺, CD25⁺, CD45RA⁺and Foxp3⁺proteins at higher levels than iTregs not expanded over a MSC feeder cell layer.